The HAE pharmaceutical landscape is set for unprecedented expansion as a large proportion of pipeline drugs are found in Phase III.

Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.

The EMA’s CHMP delivered two positive opinions, which will likely see an expansion of Novo Nordisk’s Wegovy offerings in Europe.

The EMA's CHMP has issued a positive opinion recommending approval of Pierre Fabre Laboratories’ Braftovi to treat mCRC with BRAFV600E mutations.

The University of Edinburgh scientists have developed a new cell therapy aiming to provide a potential alternative to liver transplants for patients with advanced liver disease.

AstraZeneca and Daiichi Sankyo have secured approval from the US FDA for Datroway (datopotamab deruxtecan) to treat metastatic TNBC.

Takeda has been ordered to pay $885m – potentially rising to $2.5bn – after a landmark court case verdict found the Japanese pharma company liable for a conspired arrangement ...

Eli Lilly has acquired Engage Bio and its preclinical, non-viral DNA delivery platform. Credit: Tada Images / Shutterstock.com. Pharmaceutical giant Eli Lilly has agreed to acquire Engage Biologics ...

The FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for two new indications in HER2-positive early breast cancer.

Four cancer drugs have got the FDA nod in May thus far, with approvals spanning haematological and solid tumour indications.

Bristol Myers Squibb (BMS) has signed a strategic agreement with Anthropic to implement its Claude platform across its global operations.

Gilead Sciences has concluded its acquisition of Germany-based biotechnology company Tubulis in a transaction valued at up to $5bn.